Roth Capital Reiterates Buy Rating for Aptose Biosciences Inc. (APTO)

Aptose Biosciences Inc. (NASDAQ:APTO)‘s stock had its “buy” rating reissued by Roth Capital in a note issued to investors on Friday. They currently have a $8.00 price target on the stock. Roth Capital’s target price points to a potential upside of 263.64% from the company’s previous close.

Several other research analysts have also recently weighed in on the company. Canaccord Genuity reiterated a “buy” rating and set a $7.00 price objective on shares of Aptose Biosciences in a research report on Saturday. Zacks Investment Research raised Aptose Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday, October 11th. RBC Capital Markets reissued an “outperform” rating on shares of Aptose Biosciences in a report on Tuesday, September 13th. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $23.00 target price on shares of Aptose Biosciences in a report on Saturday, June 25th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $12.30.

Analyst Recommendations for Aptose Biosciences (NASDAQ:APTO)

Shares of Aptose Biosciences (NASDAQ:APTO) opened at 2.20 on Friday. The company’s market capitalization is $28.36 million. The firm’s 50-day moving average price is $2.22 and its 200 day moving average price is $2.46. Aptose Biosciences has a one year low of $1.92 and a one year high of $6.40.

A hedge fund recently bought a new stake in Aptose Biosciences stock. Bank of Montreal Can acquired a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 52,624 shares of the company’s stock, valued at approximately $128,000. Bank of Montreal Can owned about 0.43% of Aptose Biosciences as of its most recent SEC filing. 19.47% of the stock is owned by institutional investors and hedge funds.

About Aptose Biosciences

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

5 Day Chart for NASDAQ:APTO

Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

McDonald’s Keeping As Much As 25% in Hong Kong and China Stores
McDonald’s Keeping As Much As 25% in Hong Kong and China Stores
President Obama Take Steps to Block Chip Maker Acquisition by Chinese Company
President Obama Take Steps to Block Chip Maker Acquisition by Chinese Company
GoPro Planning to Cut 200 Jobs
GoPro Planning to Cut 200 Jobs
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Retailers Anticipating Strong Support for Small Business Saturday
Retailers Anticipating Strong Support for Small Business Saturday
Eli Lilly Alzheimer’s Drug Does Not Pass the Test
Eli Lilly Alzheimer’s Drug Does Not Pass the Test


 
© 2006-2016 Ticker Report. Google+.